Skip to content
DID YOU MISS THE MEETING?
Should your pharmacy consider 503B outsourcing? What are the opportunities, costs, and regulatory considerations?
Join us for a discussion of the 503B outsourcing facility model and how it differs from traditional pharmacy compounding. We’ll explore the current 503B market, capital and operational requirements, regulatory differences, and important considerations for pharmacies evaluating whether 503B may be right for their business.
The discussion will also include a separate look at controlled substances and the additional regulatory requirements and considerations that apply.
Whether you are considering entering the 503B space, partnering with a 503B facility, or simply want to better understand the differences, this SIG will provide valuable insight to help you make informed decisions.
Join us for this informative and timely discussion on one of the important questions facing compounding pharmacies today.
Erik Tosh, RPh, FACA, brings more than 40 years of pharmacy experience and nearly five decades of experience in healthcare, with a career spanning hospital pharmacy, independent community pharmacy, pharmaceutical compounding, and industry leadership. His extensive compounding experience includes serving as Director of Operations for a large sterile compounding facility that later became registered as a 503B outsourcing facility. In that role, he oversaw operations that included production, regulatory and compliance activities, purchasing, shipping, and the preparation of high-risk compounded medications for hospitals across the United States.
Tosh later served as Vice President of Compounding Support Services at Letco Medical, where he led compounding support initiatives, developed continuing education programs, provided technical training, and worked closely with professional pharmacy organizations. He retired in 2021.
In addition to his industry experience, Tosh has served as adjunct faculty at Western University College of Pharmacy and has presented ACPE-accredited education on pharmaceutical compounding. He is a past President and Chairman of the International Academy of Compounding Pharmacists and has contributed to professional publications including Remington: The Science and Practice of Pharmacy and the International Journal of Pharmaceutical Compounding.
Considering the move to 503B? Join us for a discussion of what it takes to start or transition to a 503B Outsourcing Facility. We’ll begin with an overview of the key considerations involved, then open the conversation for attendees to ask questions, share experiences, and exchange perspectives.
This meeting will not offer CE.
LISTEN NOW
